$2.95
0.34%
Downside
Day's Volatility :5.16%
Upside
4.84%
67.12%
Downside
52 Weeks Volatility :75.75%
Upside
26.25%
Period | Trevi Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | 20.9% | 0.0% |
6 Months | 0.0% | 0.0% |
1 Year | 39.81% | 0.0% |
3 Years | 25.0% | -22.3% |
Market Capitalization | 225.0M |
Book Value | $0.91 |
Earnings Per Share (EPS) | -0.36 |
Wall Street Target Price | 9.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -30.88% |
Return On Equity TTM | -48.09% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -43.0M |
Diluted Eps TTM | -0.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.47 |
EPS Estimate Next Year | -0.5 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.1 |
What analysts predicted
Upside of 205.08%
Sell
Neutral
Buy
Trevi Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Trevi Therapeutics Inc | 13.9% | 0.0% | 39.81% | 25.0% | 25.0% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Trevi Therapeutics Inc | NA | NA | NA | -0.47 | -0.48 | -0.31 | NA | 0.91 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Trevi Therapeutics Inc | Buy | $225.0M | 25.0% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
NEA Management Company, LLC
Rubric Capital Management LP
Viking Global Investors LP
VR Adviser, LLC
BlackRock Inc
Logos Global Management LP
trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can
Organization | Trevi Therapeutics Inc |
Employees | 26 |
CEO | Ms. Jennifer L. Good |
Industry | Pharmaceuticals: Major |
A Spac I Acquisition Corp
$2.95
-4.84%
Keyarch Acquisition Corp
$2.95
-4.84%
Connexa Sports Technologies Inc
$2.95
-4.84%
Us Value Etf
$2.95
-4.84%
First Wave Biopharma Inc
$2.95
-4.84%
Global X Msci Next Emerging
$2.95
-4.84%
Fat Projects Acquisition Corp
$2.95
-4.84%
Capital Link Global Fintech
$2.95
-4.84%
Applied Uv Inc
$2.95
-4.84%